肺动脉高压
氧化应激
肺动脉
右心室肥大
医学
药理学
基因敲除
氧化磷酸化
血管平滑肌
缺氧(环境)
治疗效果
抗氧化剂
内皮
肌肉肥大
KEAP1型
内科学
内皮功能障碍
心肌细胞
生物能学
线粒体ROS
内分泌学
癌症研究
活性氧
心脏病学
化学
线粒体
下调和上调
炎症
治疗方法
呼吸系统
平衡
作者
Chuangjia Huang,June Bai,Ang Luo,Lei Yang,Xingting Wang,L. Dang,Changlei Bao,Jinsheng Zhu,Z Chen,Bitao Wu,Jintao Long,Jieyi Feng,Zinan Luo,Yingying Xiao,Hanliang Sun,Shuxin Liang,Li Zhang,Jing Hua,Deming Gou,Ankit A. Desai
出处
期刊:Hypertension
[Lippincott Williams & Wilkins]
日期:2026-07-27
标识
DOI:10.1161/hypertensionaha.126.26711
摘要
BACKGROUND: Pulmonary arterial hypertension is a progressive and life-threatening disorder characterized by elevated pulmonary arterial pressure, right ventricular hypertrophy, and eventual right heart failure. Omaveloxolone, an orally bioavailable synthetic triterpenoid recently approved for Friedreich's ataxia, improves mitochondrial bioenergetics and restores redox homeostasis. We investigated whether pharmacological activation of NRF2 (nuclear factor erythroid 2-related factor 2) by Omaveloxolone confers therapeutic benefit in pulmonary hypertension (PH). METHODS: The effects of Omaveloxolone were evaluated in chronic hypoxia-induced PH in mice, monocrotaline-induced PH in rats, and sugen/hypoxia-induced PH in rats, together with studies in human pulmonary artery endothelial and smooth muscle cells. RESULTS: NRF2 expression and nuclear localization were reduced in PH lungs and hypoxia-exposed cells, whereas Omaveloxolone restored NRF2 activity and increased downstream antioxidant enzymes. In endothelial cells, Omaveloxolone reduced oxidative stress, suppressed inflammatory signaling, and inhibited endothelial-to-mesenchymal transition. In smooth muscle cells, it attenuated oxidative stress and normalized abnormal proliferation, migration, and apoptosis. Omaveloxolone reduced HIF (hypoxia-inducible factor)-2α accumulation in endothelial cells and inhibited HIF-1α stabilization in smooth muscle cells. NRF2 knockdown attenuated these effects, supporting pathway dependency. Omaveloxolone attenuated PH, reduced right ventricular hypertrophy and vascular remodeling, and improved right ventricular function across hypoxia, monocrotaline, and sugen/hypoxia models under both preventive and therapeutic regimens. CONCLUSIONS: These findings demonstrate that Omaveloxolone exerts disease-modifying effects in PH by activating NRF2-dependent cytoprotective pathways, reducing oxidative stress, and suppressing inflammation, supporting its translational potential as a therapeutic strategy.